Table 3.
LncRNA | Cancer type | Expression | Model | Hallmark | Molecular mechanism | Function | Reference |
---|---|---|---|---|---|---|---|
TNK2-AS1 | NSCLC | Up | Vitro | Angiogenesis | Interacts with STAT3 to upregulate VEGFA expression | Promotes angiogenesis and metastasis | Wang et al117 |
LOC100132354 | LAD | Up | Vitro | Angiogenesis | Activates VEGFA/VEGFR2 pathway | Promotes angiogenesis and metastasis | Wang et al118 |
LINC00667 | NSCLC | Up | Vitro and vivo | Angiogenesis | Stabilizes VEGFA mRNA by EIF4A3 | Promotes angiogenesis and metastasis | Yang et al119 |
Lnc-EPIC1 | NSCLC | Up | Vitro and vivo | Angiogenesis | Activates Ang2/Tie2 pathway | Promotes angiogenesis and metastasis | Hou et al120 |
LCPAT1 | NSCLC | Up | Vitro | Autophagy | Promotes smoking and PM-2.5-joint induced autophagy | Promotes autophagy and metastasis | Lin et al121 |
Loc146880 | LAD | Up | Vitro | Autophagy | PM-2.5 induce ROS production to elevate its
expression Promotes PM-2.5-induced autophagy |
Promotes autophagy and metastasis | Deng et al122 |
TSLNC8 | NSCLC | Down | Vitro | Autophagy | Inhibits STAT3/HIF-1α pathway | Inhibits autophagy and metastasis | Fan et al123 |
IGFBP4-1 | NSCLC | Up | Vitro | Aerobic glycolysis | Increasing the expression of HK2 | Promotes glycolysis and metastasis | Yang et al124 |
AC020978 | NSCLC | Up | Vitro | Aerobic glycolysis | Prevents PKM2 from ubiquitin-mediated degradation and increases PKM2-enhanced HIF-1α transcription activity | Promotes glycolysis and metastasis | Hua et al125 |
LINC01537 | NSCLC | Down | Vitro | Aerobic glycolysis | Inhibits PGK1 expression by targeting PDE2A | Inhibits glycolysis and metastasis | Gong et al126 |
NEAT1 | NSCLC | Up | Vitro and vivo | Immune escape | Downregulates tumor-infiltration cytotoxic T cells through cGAS/STING/IFN pathway | Promotes immune escape and metastasis | Ma et al127 and Chen et al128 |
NKILA | NSCLC | Up | Vitro and vivo | Immune escape | Promotes AICD of CTLs via NF-κB pathway | Promotes immune escape and metastasis | Huang et al129 |
HOTAIRM1 | LAD | Down | Vitro and vivo | Immune escape | Inhibits immunosuppressive activity of MDSCs | Inhibits immune escape and metastasis | Tian et al130 and Chen et al131 |
Abbreviations: AICD, activation-induced cell death; Ang2, angiopoietin 2; cGAS, cyclic GMP-AMP synthase; CTL, cytotoxic T lymphocyte; EIF4A3, eukaryotic translation initiation factor 4A3; HIF-1α, hypoxia-inducible factor-1α; HK2, hexokinase 2; HOTAIR, HOX transcript antisense intergenic RNA; HOTAIRM1, HOTAIR myeloid-specific 1; IFN, interferon; IGFBP4-1, insulin-like growth factor binding protein 4 to 1; LAD, lung adenocarcinoma; LCPAT1, lung cancer progression-associated transcript 1; Lnc-EPIC1, long noncoding RNA EPIC1; MDSC, myeloid-derived suppressor cell; lncRNA, long noncoding RNA; mRNA, messenger RNA; NEAT1, nuclear paraspeckle assembly transcript 1; NF-κB, nuclear factor kappa B; NKILA, NF-κB interacting lncRNA; NSCLC, nonsmall cell lung cancer; PDE2A; phosphodiesterase 2A; PGK1, phosphoglycerate kinase 1; PKM2, M2 isoform of pyruvate kinase; PM-2.5, particulate matter-2.5; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription 3; STING, stimulator of interferon gene; TNK2-AS1, tyrosine kinase nonreceptor 2 antisense RNA 1; TSLNC8, tumor-suppressive role of lncRNA on chromosome 8p12; VEGFA, vascular endothelial growth factor A; VEGFR2, vascular endothelial growth factor receptor 2.